Targeted CNS Delivery Using Human MiniPromoters and Demonstrated Compatibility with Adeno-Associated Viral Vectors.

"C.N.d.L., E.P.-C., C.A.D., S.J.M.J., R.A.H., D.G., W.W.W., E.M.S., and the University of British Columbia have filed for US patents on a subset of the MiniPs. W.W.H. and the University of Florida have a financial interest in the use of AAV therapies, and own equity in a company (AGTC) that might, in the future, commercialize some aspects of this work."

"This work was supported as part of the Pleiades Promoter Project by grants from Genome Canada (grant number: 20R03061); Genome British Columbia (grant number: 045PLE); GlaxoSmithKline R&D (grant number: 20R62517); BC Mental Health and Addiction Services (grant number: 20R62601); Child and Family Research Institute (grant number: 20R42459); University of British Columbia (UBC) Institute of Mental Health (grant number: 20R78630); and UBC Office of the Vice President Research (grant number: 20R78603) to S.J.M.J., R.A.H., D.G., W.W.W., and E.M.S. We also acknowledge partial support of this work from the National Institutes of Health (NIH) (grant number: EY021721) and grants from the Macula Vision Research Foundation, Foundation Fighting Blindness, Eldon Family Foundation, Overstreet Fund, and Research to Prevent Blindness to W.W.H. In addition, we acknowledge partial support from NIH (grant number: R01GM084875) to W.W.W. Finally, we acknowledge salary support from Canadian Research Chairs to D.G. and E.M.S., Canadian Institutes of Health Research New Investigator Award to W.W.W., Canadian Institutes of Health Research Canada Graduate Scholarships to C.N.d.L., and Michael Smith Foundation for Health Research Awards to C.N.d.L., S.J.M.J., R.A.H., and W.W.W."